Payment overview · 2025
General Payments
$7,734.78
155 reported records · 48 companies
Healthcare provider profile · identity verified
Samir Mazharuddin
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · WEBSTER, TX · NPI 1922442995
Verified facts
What the public records show
CMS Open Payments records show Samir Mazharuddin received $7,734.78 in general payments during 2025 across 155 reported records.
Janssen Biotech, Inc. accounted for 28.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 82 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Calquence, Jakafi, Kisqali, Ojjaara, Venclexta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VENCLEXTA as an associated drug or biological on 10417 records involving 4944 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Venclexta by this doctor in 2024.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IBRANCE as an associated drug or biological on 54 records involving 52 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ibrance by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CALQUENCE as an associated drug or biological on 8404 records involving 3935 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Calquence by this doctor in 2024.
AstraZeneca UK Limited reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CALQUENCE as an associated drug or biological on 91 records involving 44 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Calquence by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Eliquis by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Eliquis by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Venclexta as an associated drug or biological on 2896 records involving 2018 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Venclexta by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OJJAARA as an associated drug or biological on 12602 records involving 5639 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ojjaara by this doctor in 2024.
Incyte Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JAKAFI as an associated drug or biological on 14854 records involving 6477 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Jakafi by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Xarelto by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported KISQALI as an associated drug or biological on 31637 records involving 7959 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Kisqali by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IBRANCE as an associated drug or biological on 11505 records involving 4934 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ibrance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $2,188.73 | 28.3% | 20 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $1,834.68 | 23.7% | 8 | 2025 |
| Cardinal Health 110 LLC | Unresolved — no canonical attribution shown | $400.00 | 5.2% | 2 | 2025 |
| Tempus AI, Inc | Unresolved — no canonical attribution shown | $374.85 | 4.8% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $333.84 | 4.3% | 9 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $182.15 | 2.4% | 7 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $158.44 | 2.0% | 7 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $141.32 | 1.8% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $129.60 | 1.7% | 5 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $122.92 | 1.6% | 5 | 2025 |
| AstraZeneca UK Limited | Unresolved — no canonical attribution shown | $121.99 | 1.6% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $110.60 | 1.4% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $96.99 | 1.2% | 4 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $86.40 | 1.1% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $84.46 | 1.1% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $79.49 | 1.0% | 3 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $78.53 | 1.0% | 4 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $75.63 | 1.0% | 3 | 2025 |
| TerSera Therapeutics LLC | Unresolved — no canonical attribution shown | $75.09 | 1.0% | 3 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $74.81 | 1.0% | 2 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $69.50 | 0.9% | 3 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $69.14 | 0.9% | 3 | 2025 |
| Aveo Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $66.90 | 0.9% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $64.78 | 0.8% | 2 | 2025 |
| Kite Pharma, Inc. | Unresolved — no canonical attribution shown | $62.70 | 0.8% | 2 | 2025 |
| Genmab U.S., Inc. | Unresolved — no canonical attribution shown | $61.65 | 0.8% | 3 | 2025 |
| Stemline Therapeutics Inc. | Unresolved — no canonical attribution shown | $56.90 | 0.7% | 3 | 2025 |
| TAIHO ONCOLOGY, INC. | Unresolved — no canonical attribution shown | $52.62 | 0.7% | 2 | 2025 |
| Janssen Scientific Affairs, LLC | Unresolved — no canonical attribution shown | $44.25 | 0.6% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $36.81 | 0.5% | 2 | 2025 |
| PharmaEssentia USA Corporation | Unresolved — no canonical attribution shown | $36.27 | 0.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.20 | 0.4% | 1 | 2025 |
| Rigel Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.26 | 0.4% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $29.06 | 0.4% | 1 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $26.93 | 0.3% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $26.34 | 0.3% | 1 | 2025 |
| Deciphera Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $25.44 | 0.3% | 1 | 2025 |
| Iovance Biotherapeutics, Inc. | Unresolved — no canonical attribution shown | $23.78 | 0.3% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.86 | 0.3% | 1 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $19.32 | 0.2% | 1 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $18.22 | 0.2% | 1 | 2025 |
| Caris MPI, Inc. | Unresolved — no canonical attribution shown | $17.89 | 0.2% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $17.25 | 0.2% | 1 | 2025 |
| pharmaand GmbH | Unresolved — no canonical attribution shown | $17.25 | 0.2% | 1 | 2025 |
| Karyopharm Therapeutics Inc. | Unresolved — no canonical attribution shown | $16.82 | 0.2% | 1 | 2025 |
| PUMA BIOTECHNOLOGY, INC. | Unresolved — no canonical attribution shown | $16.75 | 0.2% | 1 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.91 | 0.2% | 1 | 2025 |
| Adaptive Biotechnologies Corporation | Unresolved — no canonical attribution shown | $13.46 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,836.80 | 146 |
| Consulting Fee | $3,650.00 | 4 |
| Education | $192.94 | 2 |
| Travel and Lodging | $55.04 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DARZALEX Normalized: darzalex |
Biological, Drug | Janssen Biotech, Inc., Janssen Scientific Affairs, LLC | $1,906.46 | 10 | 2025 |
Source payment records
|
|||||
| CALQUENCE Normalized: calquence |
Drug | AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited | $1,848.68 | 4 | 2025 |
Source payment records
|
|||||
| XT CDX Normalized: xt cdx |
Device | Tempus AI, Inc | $374.85 | 10 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $197.79 | 5 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC. | $197.71 | 4 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $158.44 | 7 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $128.73 | 6 | 2025 |
Source payment records
|
|||||
| TALVEY Normalized: talvey |
Biological | Janssen Biotech, Inc., Janssen Scientific Affairs, LLC | $120.45 | 4 | 2025 |
Source payment records
|
|||||
| PLUVICTO Normalized: pluvicto |
Drug | Novartis Pharmaceuticals Corporation | $105.86 | 4 | 2025 |
Source payment records
|
|||||
| ENHERTU Normalized: enhertu |
Biological, Drug | AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc. | $103.26 | 4 | 2025 |
Source payment records
|
|||||
| OPDUALAG Normalized: opdualag |
Drug | Celgene Corporation, E.R. Squibb & Sons, L.L.C. | $102.85 | 4 | 2025 |
Source payment records
|
|||||
| ELAHERE Normalized: elahere |
Drug | ABBVIE INC. | $102.32 | 4 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $91.45 | 4 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $86.40 | 4 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Biological, Drug | AstraZeneca Pharmaceuticals LP, Merck Sharp & Dohme LLC | $86.23 | 3 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $78.53 | 4 | 2025 |
Source payment records
|
|||||
| ZEPZELCA Normalized: zepzelca |
Drug | JAZZ PHARMACEUTICALS INC. | $74.81 | 2 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $73.65 | 3 | 2025 |
Source payment records
|
|||||
| AKEEGA Normalized: akeega |
Drug | Janssen Biotech, Inc. | $73.40 | 3 | 2025 |
Source payment records
|
|||||
| Xtandi Normalized: xtandi |
Drug | Astellas Pharma US Inc | $73.01 | 5 | 2025 |
Source payment records
|
|||||
| IMBRUVICA Normalized: imbruvica |
Drug | ABBVIE INC. | $72.75 | 3 | 2025 |
Source payment records
|
|||||
| FOTIVDA Normalized: fotivda |
Drug | Aveo Pharmaceuticals, Inc. | $66.90 | 4 | 2025 |
Source payment records
|
|||||
| CARVYKTI Normalized: carvykti |
Drug | Janssen Biotech, Inc., Janssen Scientific Affairs, LLC | $66.69 | 2 | 2025 |
Source payment records
|
|||||
| TECVAYLI Normalized: tecvayli |
Biological | Janssen Biotech, Inc., Janssen Scientific Affairs, LLC | $66.27 | 2 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $64.78 | 2 | 2025 |
Source payment records
|
|||||
| Yescarta Normalized: yescarta |
Drug | Kite Pharma, Inc. | $62.70 | 2 | 2025 |
Source payment records
|
|||||
| Tivdak Normalized: tivdak |
Drug | Genmab U.S., Inc. | $61.65 | 3 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation | $57.62 | 2 | 2025 |
Source payment records
|
|||||
| Orserdu Normalized: orserdu |
Drug | Stemline Therapeutics Inc. | $56.90 | 3 | 2025 |
Source payment records
|
|||||
| IMFINZI Normalized: imfinzi |
Biological | AstraZeneca Pharmaceuticals LP | $53.47 | 3 | 2025 |
Source payment records
|
|||||
| INQOVI Normalized: inqovi |
Drug | TAIHO ONCOLOGY, INC. | $52.62 | 2 | 2025 |
Source payment records
|
|||||
| LONSURF Normalized: lonsurf |
Drug | TAIHO ONCOLOGY, INC. | $52.62 | 2 | 2025 |
Source payment records
|
|||||
| Onivyde Normalized: onivyde |
Drug | Ipsen Biopharmaceuticals, Inc | $51.44 | 2 | 2025 |
Source payment records
|
|||||
| Zoladex Normalized: zoladex |
Drug | TerSera Therapeutics LLC | $50.75 | 2 | 2025 |
Source payment records
|
|||||
| ADCETRIS Normalized: adcetris |
Biological | PFIZER INC. | $50.46 | 2 | 2025 |
Source payment records
|
|||||
| ELREXFIO Normalized: elrexfio |
Drug | PFIZER INC. | $50.46 | 2 | 2025 |
Source payment records
|
|||||
| Itovebi Normalized: itovebi |
Biological | Genentech USA, Inc. | $46.33 | 2 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $46.07 | 2 | 2025 |
Source payment records
|
|||||
| BESREMI Normalized: besremi |
Drug | PharmaEssentia USA Corporation | $36.27 | 2 | 2025 |
Source payment records
|
|||||
| RUBRACA Normalized: rubraca |
Drug | TOLMAR, INC., pharmaand GmbH | $34.50 | 2 | 2025 |
Source payment records
|
|||||
| Stivarga Normalized: stivarga |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $34.10 | 1 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological | PFIZER INC. | $34.00 | 2 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Drug | ABBVIE INC. | $33.81 | 1 | 2025 |
Source payment records
|
|||||
| ICLUSIG Normalized: iclusig |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $31.71 | 1 | 2025 |
Source payment records
|
|||||
| Xofigo Normalized: xofigo |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $30.68 | 1 | 2025 |
Source payment records
|
|||||
| JAYPIRCA Normalized: jaypirca |
Drug | Lilly USA, LLC | $30.20 | 1 | 2025 |
Source payment records
|
|||||
| VERZENIO Normalized: verzenio |
Drug | Lilly USA, LLC | $30.20 | 1 | 2025 |
Source payment records
|
|||||
| Gavreto Normalized: gavreto |
Drug | Rigel Pharmaceuticals, Inc. | $29.26 | 1 | 2025 |
Source payment records
|
|||||
| Rezlidhia Normalized: rezlidhia |
Drug | Rigel Pharmaceuticals, Inc. | $29.26 | 1 | 2025 |
Source payment records
|
|||||
| TAVALISSE Normalized: tavalisse |
Drug | Rigel Pharmaceuticals, Inc. | $29.26 | 1 | 2025 |
Source payment records
|
|||||
| TheraSphere Y90 Glass Microspheres 10 GBq Normalized: therasphere y90 glass microspheres 10 gbq |
Device | Boston Scientific Corporation | $29.06 | 1 | 2025 |
Source payment records
|
|||||
| KEYTRUDA QLEX Normalized: keytruda qlex |
Biological | Merck Sharp & Dohme LLC | $27.95 | 1 | 2025 |
Source payment records
|
|||||
| DATROWAY Normalized: datroway |
Drug | Daiichi Sankyo Inc. | $27.57 | 1 | 2025 |
Source payment records
|
|||||
| NINLARO Normalized: ninlaro |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $26.41 | 1 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $26.34 | 1 | 2025 |
Source payment records
|
|||||
| QINLOCK Normalized: qinlock |
Drug | Deciphera Pharmaceuticals Inc. | $25.44 | 1 | 2025 |
Source payment records
|
|||||
| ROMVIMZA Normalized: romvimza |
Drug | Deciphera Pharmaceuticals Inc. | $25.44 | 1 | 2025 |
Source payment records
|
|||||
| Xermelo Normalized: xermelo |
Drug | TerSera Therapeutics LLC | $24.34 | 1 | 2025 |
Source payment records
|
|||||
| Tazverik Normalized: tazverik |
Drug | Ipsen Biopharmaceuticals, Inc | $24.19 | 1 | 2025 |
Source payment records
|
|||||
| Amtagvi Normalized: amtagvi |
Drug | Iovance Biotherapeutics, Inc. | $23.78 | 1 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $23.74 | 1 | 2025 |
Source payment records
|
|||||
| MONJUVI Normalized: monjuvi |
Drug | Incyte Corporation | $23.43 | 1 | 2025 |
Source payment records
|
|||||
| BLENREP Normalized: blenrep |
Biological | GlaxoSmithKline, LLC. | $23.34 | 1 | 2025 |
Source payment records
|
|||||
| Alecensa Normalized: alecensa |
Biological | Genentech USA, Inc. | $22.81 | 1 | 2025 |
Source payment records
|
|||||
| FRUZAQLA Normalized: fruzaqla |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $21.37 | 1 | 2025 |
Source payment records
|
|||||
| NIKTIMVO Normalized: niktimvo |
Drug | Incyte Corporation | $21.29 | 1 | 2025 |
Source payment records
|
|||||
| Vanflyta Normalized: vanflyta |
Drug | Daiichi Sankyo Inc. | $21.12 | 1 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $20.45 | 1 | 2025 |
Source payment records
|
|||||
| DANZITEN Normalized: danziten |
Drug | Azurity Pharmaceuticals, Inc. | $19.86 | 1 | 2025 |
Source payment records
|
|||||
| ENJAYMO Normalized: enjaymo |
Drug | RECORDATI_RARE_DISEASES_INC. | $19.32 | 1 | 2025 |
Source payment records
|
|||||
| BRAFTOVI Normalized: braftovi |
Drug | ARRAY BIOPHARMA INC | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| MEKTOVI Normalized: mektovi |
Drug | ARRAY BIOPHARMA INC | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| TUKYSA Normalized: tukysa |
Drug | ARRAY BIOPHARMA INC | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| MI CANCER SEEK Normalized: mi cancer seek |
Device | Caris MPI, Inc. | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| WELIREG Normalized: welireg |
Drug | Merck Sharp & Dohme LLC | $17.56 | 1 | 2025 |
Source payment records
|
|||||
| ELIGARD Normalized: eligard |
Drug | TOLMAR, INC. | $17.25 | 1 | 2025 |
Source payment records
|
|||||
| INLYTA Normalized: inlyta |
Drug | PFIZER INC. | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| XPOVIO Normalized: xpovio |
Drug | Karyopharm Therapeutics Inc. | $16.82 | 1 | 2025 |
Source payment records
|
|||||
| NERLYNX Normalized: nerlynx |
Drug | PUMA BIOTECHNOLOGY, INC. | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| LYNOZYFIC Normalized: lynozyfic |
Biological | Regeneron Healthcare Solutions, Inc. | $16.36 | 1 | 2025 |
Source payment records
|
|||||
| Vyloy Normalized: vyloy |
Drug | Astellas Pharma US Inc | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| clonoSEQ Normalized: clonoseq |
Device | Adaptive Biotechnologies Corporation | $13.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CALQUENCE calquence |
2025 | Calquence | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JAKAFI jakafi |
2025 | Jakafi | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| KISQALI kisqali |
2025 | Kisqali | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OJJAARA ojjaara |
2025 | Ojjaara | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VENCLEXTA venclexta |
2025 | Venclexta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VENCLEXTA open payments reported associated product |
CMS Open Payments — General Payments 10417 supporting records · 4944 recipient NPIs · example record 1201353144 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | IBRANCE open payments reported associated product |
CMS Open Payments — General Payments 54 supporting records · 52 recipient NPIs · example record 1228804288 |
Ibrance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | CALQUENCE open payments reported associated product |
CMS Open Payments — General Payments 8404 supporting records · 3935 recipient NPIs · example record 1206131382 |
Calquence · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| AstraZeneca UK Limited Exact reporting entity; no affiliate inference |
2025 | CALQUENCE open payments reported associated product |
CMS Open Payments — General Payments 91 supporting records · 44 recipient NPIs · example record 1202913748 |
Calquence · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
77 | 19 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
77 | 19 |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Venclexta open payments reported associated product |
CMS Open Payments — General Payments 2896 supporting records · 2018 recipient NPIs · example record 1211488584 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | OJJAARA open payments reported associated product |
CMS Open Payments — General Payments 12602 supporting records · 5639 recipient NPIs · example record 1190332357 |
Ojjaara · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Incyte Corporation Exact reporting entity; no affiliate inference |
2025 | JAKAFI open payments reported associated product |
CMS Open Payments — General Payments 14854 supporting records · 6477 recipient NPIs · example record 1225959940 |
Jakafi · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | KISQALI open payments reported associated product |
CMS Open Payments — General Payments 31637 supporting records · 7959 recipient NPIs · example record 1200004789 |
Kisqali · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
77 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | IBRANCE open payments reported associated product |
CMS Open Payments — General Payments 11505 supporting records · 4934 recipient NPIs · example record 1228794164 |
Ibrance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Anastrozole | Anastrozole | 141 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 131 | 48 |
| Ondansetron Odt | Ondansetron | 127 | 61 |
| Eliquis | Apixaban | 77 | 19 |
| Letrozole | Letrozole | 59 | 14 |
| Prednisone | Prednisone | 51 | 13 |
| Calquence | Acalabrutinib Maleate | 49 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 44 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 42 | 19 |
| Allopurinol | Allopurinol | 34 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | suppressed |
| Carvedilol | Carvedilol | 31 | suppressed |
| Lorazepam | Lorazepam | 31 | 12 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 29 | suppressed |
| Furosemide | Furosemide | 28 | 12 |
| Hydroxyurea | Hydroxyurea | 27 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 27 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Gabapentin | Gabapentin | 24 | suppressed |
| Dexamethasone | Dexamethasone | 22 | 13 |
| Amoxicillin | Amoxicillin | 21 | 14 |
| Alprazolam | Alprazolam | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | suppressed |
| Omeprazole | Omeprazole | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 18 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 18 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Metformin Hcl | Metformin Hcl | 17 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 17 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 17 | suppressed |
| Lenalidomide | Lenalidomide | 16 | suppressed |
| Revlimid | Lenalidomide | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 15 | suppressed |
| Constulose | Lactulose | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Jakafi | Ruxolitinib Phosphate | 14 | suppressed |
| Kisqali | Ribociclib Succinate | 14 | suppressed |
| Losartan Potassium | Losartan Potassium | 14 | suppressed |
| Ojjaara | Momelotinib Dihydrochloride | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 12 | 12 |
| Spironolactone | Spironolactone | 12 | suppressed |
| Venclexta | Venetoclax | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Ibrance | Palbociclib | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $7,734.78 · 155 records | Janssen Biotech, Inc. | ADCETRIS, AKEEGA, Alecensa, Amtagvi, BESREMI, BLENREP, BRAFTOVI, CALQUENCE, CARVYKTI, DANZITEN, DARZALEX, DATROWAY, ELAHERE, ELIGARD, ELREXFIO, ENHERTU, ENJAYMO, EPKINLY, ERLEADA, FOTIVDA, FRUZAQLA, GIVLAARI, Gavreto, ICLUSIG, IMBRUVICA, IMFINZI, INLYTA, INQOVI, Itovebi, JAKAFI, JAYPIRCA, KEYTRUDA, KEYTRUDA QLEX, KISQALI, LIBTAYO, LONSURF, LYNOZYFIC, LYNPARZA, Lenvima, MEKTOVI, MI CANCER SEEK, MONJUVI, NERLYNX, NIKTIMVO, NINLARO, Nubeqa, OJJAARA, OPDIVO, OPDUALAG, Onivyde, Orserdu, PADCEV, PLUVICTO, QINLOCK, REBLOZYL, ROMVIMZA, RUBRACA, RYBREVANT, Rezlidhia, Stivarga, TALVEY, TAVALISSE, TECVAYLI, TUKYSA, Tazverik, TheraSphere Y90 Glass Microspheres 10 GBq, Tivdak, Trodelvy, VENCLEXTA, VERZENIO, Vanflyta, Vyloy, WELIREG, XPOVIO, XT CDX, Xermelo, Xofigo, Xtandi, Yescarta, ZEPZELCA, Zoladex, clonoSEQ | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Calquence play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error